Italy (IT)

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (2021) Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, et al. Journal article Does methotrexate influence COVID-19 infection? Case series and mechanistic data (2021) Schälter F, Dürholz K, Bucci L, Burmester GR, Caporali R, Figuereido C, Cobra JF, et al. Journal article, Original article Pedicled Strip of Quadriceps Tendon Graft for Primary Medial Patellofemoral Ligament Reconstruction in Recurrent Patellofemoral Instability: A Systematic Review (2021) Migliorini F, Trivellas A, Eschweiler J, Betsch M, Tingart M, Maffulli N Journal article, Review article Failure and progression to total hip arthroplasty among the treatments for femoral head osteonecrosis: A Bayesian network meta-analysis (2021) Migliorini F, Maffulli N, Baroncini A, Eschweiler J, Tingart M, Betsch M Journal article, Review article A FRAMEWORK OF POTENTIAL INTERVENTIONS TO ACCELERATE GENDER-EQUITABLE CAREER ADVANCEMENT IN ACADEMIC RHEUMATOLOGY (2021) Ovseiko PV, Gossec L, Andreoli L, Kiltz U, Van Mens L, Hassan N, Van Der Leeden M, et al. Conference contribution RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL (2021) Boers M, Conaghan PG, Schett G, Mandl P, Naredo E, Van Den Bosch F, Burgos-Vargas R, et al. Conference contribution TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY (2021) D'Agostino MA, Conaghan PG, Gaillez C, Boers M, Naredo E, Carron P, Hanova P, et al. Conference contribution EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT (2021) Kuster S, Jordan S, Elhai MD, Held U, Steigmiller K, Bruni C, Iannone F, et al. Conference contribution PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, Chatelus E, et al. Conference contribution DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE (2021) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution